The therapeutic role of Cataflam 1.5% (Diclofenac Sodium oral solution) is commonly used to help with symptomatic support by addressing pain, inflammation, and fever across several clinical contexts. The therapeutic applications of this class of medicine are considered relevant for easing symptoms related to inflammatory or irritative states and managing pain where an inflammatory component is present.

This solution is commonly used to help manage pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also applied in acute settings for post-operative and post-traumatic discomfort, the acute treatment of migraine attacks, and for the relief of pain linked to primary dysmenorrhea.

The medication helps address symptom clusters that may become intense or disruptive, assists with maintaining functional stability, and helps improve day-to-day comfort during symptomatic periods. The medication supports the patient during difficult episodes by easing distress. This supportive relief is relevant when symptoms interfere with routine activities.

---

Quick Fact: Supportive Relief for Joint Pain and Stiffness The medication is considered relevant for managing pain, tenderness, and inflammation in chronic joint conditions, and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. Therapeutic Goods Administration safety review

Cataflam 1.5% (Diclofenac Sodium Oral Solution) eligibility is strictly defined by regulatory criteria, governing who is permitted to use the medicine. Use is generally established for adults and adolescents 14 years and over; specific oral solution formulations may be available for pediatric patients aged 6 years and older.

The medicine is contraindicated in several critical populations: those with known hypersensitivity to diclofenac or other NSAIDs (including aspirin-sensitive asthma); patients with severe heart, renal, or hepatic failure; and individuals with active gastrointestinal ulceration, hemorrhage, or perforation. It is also contraindicated for pain following Coronary Artery Bypass Graft (CABG) surgery and during the last trimester of pregnancy.

Use is restricted in other groups. Older adults require cautious use at the lowest effective dose. Patients with mild to moderate renal or hepatic impairment are eligible but must undergo close monitoring. The medicine is not recommended for women who are breastfeeding or those attempting to conceive, as it may impair female fertility.

Interactions with other medicines and products

Official regulatory information for the active substance in Cataflam 1.5% documents several categories of medicines that require professional oversight, monitoring, or avoidance when co-administered.

Medicines that Require Caution or Monitoring

Medicine Category	Interaction Implication
Anticoagulants and Anti-platelet Agents (e.g., warfarin, aspirin)	Increased risk of serious bleeding events
SSRIs (Selective Serotonin Reuptake Inhibitors)	Increased risk of gastrointestinal bleeding
Antihypertensives (ACE inhibitors, ARBs)	Potential reduction in the blood pressure-lowering effect
Diuretics (e.g., furosemide, hydrochlorothiazide)	Potential for reduced diuretic effect and increased risk of kidney impairment
Lithium or Methotrexate	Potential for significantly increased plasma levels and toxicity of these medicines
Digoxin or Cyclosporine	Monitoring for increased toxicity is necessary

Restricted Combinations

• Other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), including aspirin: Concurrent use is generally restricted due to the heightened risk of adverse gastrointestinal and bleeding events.
• Coronary Artery Bypass Graft (CABG) Surgery: Use is restricted (not recommended or contraindicated) for the management of pain immediately before or after CABG surgery.
• Mifepristone: Co-administration is restricted for 8 to 12 days following the administration of mifepristone as the effectiveness of mifepristone may be reduced.

Procedural Notes

Interactions may also involve medicines that impact the CYP2C9 enzyme, which is responsible for metabolizing the active substance, potentially altering its concentration in the body. Additionally, regulatory documents for some oral formulations note that taking the product on an empty stomach may be required, as co-administration with food may reduce efficacy.

The active component, Diclofenac Sodium, influences key enzyme systems and chemical signaling pathways, thereby influencing physiological processes at the peripheral and central levels. Its mechanism is founded on three primary mechanistic domains.

Modulation of the Prostaglandin Biosynthesis Cascade

Diclofenac functions as an inhibitor of the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform. By blocking the active site, the drug halts the conversion of Arachidonic Acid into prostanoids like PGE2, which are central to chemical signaling. This action directly affects the chemical mediators involved in inflammation signaling.

Alteration of Peripheral Nociceptor Sensitization

The reduction of PGE2 concentration at the tissue level alters the chemical sensitization of peripheral nociceptors (pain-sensing nerve endings). This fundamental action modulates the activation threshold at which these fibers transmit signals, thereby influencing the magnitude of nociceptive input to the central nervous system.

Regulation of Hypothalamic Thermoregulatory Control

The mechanism extends to the brain's hypothalamus, where PGE2 is a key chemical mediator for elevating the body's temperature set-point. By inhibiting PGE2 synthesis here, the drug allows the central thermoregulatory system to reset the elevated temperature set-point, leading to modulation of the core temperature response.

How to Use Cataflam 1.5% Oral Solution

This section outlines the administration principles and dosage requirements for Diclofenac Sodium oral solution. It details the procedural steps for consumption and the limits on use.

---

Administration Scope and Protocol

The formulation is a liquid preparation intended for oral ingestion and requires specific steps before administration. The solution must be diluted immediately prior to consumption by mixing the measured dose with a small volume of plain water. This diluted mixture must then be consumed immediately.

To achieve the intended rapid systemic effect, the medication should generally be taken on an empty stomach. The use of this drug is reserved for a short duration and is not intended for continuous long-term regimens or prophylactic use.

Usage Parameter	Instruction
Route of Administration	Oral
Standard Single Dose	50 mg of Diclofenac
Maximum Daily Limit	150 mg per day
Dosing Frequency	As-needed for acute symptoms, up to three times daily (TID)
Elderly Dosing	Treatment must start with the lowest effective dose

---

Dosing and Procedural Restrictions

The administration schedule is typically as-needed (on-demand) for acute episodes, allowing for repeat doses up to the maximum daily limit of 150 mg. The dosing of this specific oral solution is not interchangeable with the dosing of other Diclofenac formulations, such as tablets or capsules, due to differences in systemic absorption. This non-interchangeability principle is a key factor for the proper use of the liquid formulation.

Research evidence / Overview of studies for Cataflam 1.5%

---

Evidence for Acute Treatment of Migraine Attacks

The evidence base includes short-term Randomized Controlled Trials (RCTs) and systematic reviews that explored the use of rapidly-absorbed diclofenac in adults experiencing acute migraine episodes. Researchers monitored outcomes related to physical discomfort and measured how quickly pain intensity shifted from baseline levels. Findings describe patterns observed related to the timing of the onset of pain change and the proportion of individuals who reported achieving a pain-free status in the first two hours. This research is specific to treating a single, acute attack; its use for preventing future episodes (prophylaxis) has not been evaluated, and there are limited data on taking a second dose.

---

Evidence for Chronic Inflammatory Joint Conditions

The research base for Diclofenac in chronic conditions like osteoarthritis and rheumatoid arthritis includes Systematic Reviews and Meta-Analyses of data from systemic forms. Studies explored how symptoms evolved in adult populations, tracking changes in physical functioning using specialized scales (like the WOMAC index) over intermediate periods. Findings describe patterns observed related to modulating symptoms such as joint pain and stiffness. The evidence quality for systemic use is broadly categorized by scientific reviews as Moderate to High. However, studies are focused on changes in symptoms and do not evaluate whether the medication impacts or reverses underlying joint damage.

---

Evidence for Acute Pain and Primary Dysmenorrhea

Research examined the role of the oral solution in evaluating symptom patterns related to general acute pain and in adult women for primary dysmenorrhea (menstrual cramps). This evidence is primarily derived from single-dose Randomized Controlled Trials (RCTs) conducted during periods of increased symptom activity. Studies monitored outcomes describing episodic or acute changes over defined intervals, tracking the total change in pain reported. Since these are acute indications, there is limited information for long-term outcomes. While the rapid absorption rate of the oral solution was observed in some studies, the clinical difference this makes compared to other rapidly absorbed diclofenac forms may be uncertain in all acute pain settings.

---

Key Uncertainties and Research Gaps

The research base highlights areas where data remains insufficient. Comparative evidence is lacking in head-to-head trials specifically comparing the 1.5% liquid solution to other rapid-release diclofenac forms to clearly differentiate clinical outcomes in all acute scenarios. Furthermore, there is a consistent limitation where long-term effects are not fully established beyond the limited follow-up durations of the primary trials. Research focusing on certain vulnerable populations, such as children and pregnant or nursing individuals, is absent, meaning research on these groups is still emerging.

Key Studies & References TGA Review of the safety and efficacy of diclofenac

Common questions about Cataflam 1.5% (FAQ)

---

Q: Is Cataflam 1.5% the same thing as Voltaren?

A: Cataflam and Voltaren are brand names for the same active drug, diclofenac. While both are nonsteroidal anti-inflammatory drugs (NSAIDs), they may contain different salt forms (such as diclofenac sodium or potassium) and come in different formulations and concentrations. These variations can affect how the drug is absorbed by the body.

Q: Why is Cataflam 1.5% sometimes prescribed over other NSAIDs?

A: Official product information notes that this liquid formulation is designed for rapid systemic absorption of diclofenac compared to some tablet forms. This characteristic is noted in product information as a factor relevant to prescribing decisions for acute pain episodes where a faster onset of action may be a goal.

Q: Can Cataflam 1.5% be used for dental pain or wisdom tooth recovery?

A: The official approved indications for systemic diclofenac formulations include the relief of acute pain. Dental pain, such as that experienced following procedures like wisdom tooth extraction, falls under the category of acute pain for which this class of medicine is commonly studied.

Q: Does taking Cataflam 1.5% on an empty stomach increase side effects?

A: The official direction is often to take the product on an empty stomach to help ensure fast absorption. However, NSAIDs carry risks for gastrointestinal side effects, and some product information indicates these risks may require monitoring if taken without food.

Q: Can Cataflam 1.5% cause drowsiness or affect alertness?

A: Regulatory documents list drowsiness and dizziness as possible side effects of the active ingredient, diclofenac. Because of these potential effects on the nervous system, official warnings indicate that a person's alertness may be impacted while using the medication.

Q: Is it safe to use Cataflam 1.5% if I occasionally drink alcohol?

A: Official warnings note that the use of alcohol should be avoided while taking diclofenac. Consuming alcohol can increase the risk of serious gastrointestinal problems, including dangerous bleeding or ulcers, when combined with this class of medication.

Q: Is Cataflam 1.5% considered an opioid or addictive?

A: No, Cataflam 1.5% is strictly classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its active ingredient, diclofenac, is not an opioid, and official documentation does not classify the medication as an addictive substance.

Q: Does Cataflam 1.5% help reduce fever?

A: Yes, the active ingredient diclofenac has antipyretic properties, which means it works to lower an elevated body temperature. Official information confirms that this is one of the therapeutic actions of the medicine.

Q: Is it possible to have an allergic reaction to Cataflam 1.5%?

A: Yes, known hypersensitivity to diclofenac or other NSAIDs is listed as a contraindication in official regulatory documents. Serious allergic-type reactions, including severe skin reactions like Stevens-Johnson syndrome and anaphylaxis, are documented risks.

Q: What are the non-medical ingredients in Cataflam 1.5%?

A: Official prescribing information, such as what is found in DailyMed or the Summary of Product Characteristics (SmPC), includes a complete list of all inactive ingredients (excipients) used in the product. These are added to formulate the liquid solution, but they do not contribute to the medical effect.

Q: What type of pain is Cataflam 1.5% most effective for?

A: The approved indications for this medicine include conditions characterized by acute pain and inflammation. This covers clinical areas such as acute migraine, dysmenorrhea (menstrual cramps), and certain chronic inflammatory joint conditions.

Q: Can Cataflam 1.5% affect my sleep?

A: Official regulatory documents list insomnia (difficulty falling or staying asleep) as a possible, though generally less common, adverse reaction associated with the active ingredient diclofenac.

Q: Is it normal if my urine looks slightly different after starting Cataflam 1.5%?

A: Changes such as bloody urine or a decrease in the amount of urine are listed as potential signs of serious renal (kidney) side effects in official warnings. Official warnings state that these changes require medical attention.

Q: What should I avoid eating or drinking while on Cataflam 1.5%?

A: Official warnings note that patients should avoid alcohol due to the increased risk of gastrointestinal bleeding. Additionally, caution or close monitoring is required with certain medicines, including other NSAIDs and blood pressure medications.

Q: Can I switch from another NSAID to Cataflam 1.5% easily?

A: Official warnings state that the concurrent use of other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is generally restricted due to the heightened risk of serious adverse events. Switching from one NSAID to another is generally recommended to be done under the supervision of a healthcare provider.

Q: What is the shelf life of Cataflam 1.5%?

A: Official regulatory documents specify the shelf life of the product, which is often listed as a specific duration from the date of manufacture. They also detail the maximum duration of time the solution can be used after the container is first opened (if applicable).

Q: Does Cataflam 1.5% interact with common supplements like Omega-3 or Turmeric?

A: While regulatory documents do not list every supplement, official warnings advise caution or monitoring with any substance that affects platelet function or blood clotting. Supplements with similar effects may carry an associated risk that requires discussion with a healthcare provider.

Q: Does Cataflam 1.5% cause water retention or swelling?

A: Official product information indicates that diclofenac, the active ingredient, may cause new or worsening hypertension (high blood pressure) and fluid retention. This fluid retention can sometimes manifest as swelling, or edema, in the hands or feet.

Q: Is it safe to use Cataflam 1.5% if I have high blood pressure?

A: Official warnings indicate that caution is advised for patients with high blood pressure. This is because NSAIDs can cause new or worsening hypertension and may potentially make it harder for prescribed blood pressure medications to work effectively.

Q: Why is proper hydration important when taking Cataflam 1.5%?

A: Official warnings state that dehydration or low blood volume should be corrected prior to use. This is emphasized because NSAIDs can increase the risk of kidney impairment, a risk that is greater in patients who are already dehydrated.

Q: What common side effects should I watch out for with Cataflam 1.5%?

A: Official warnings highlight several serious side effects that are noted in official warnings. These signs include evidence of gastrointestinal bleeding (such as black or tarry stools), symptoms of cardiovascular events (such as chest pain or weakness), and evidence of severe allergic reactions (such as rash, hives, or swelling of the face/throat).

Q: Is it normal to feel a slight stomach upset after taking Cataflam 1.5%?

A: Nausea, vomiting, and abdominal pain are explicitly listed in official documents as common gastrointestinal side effects. These are known and frequently observed occurrences associated with the use of diclofenac.

Q: How long does the effect of one dose of Cataflam 1.5% typically last?

A: Official pharmacological data indicates that the plasma elimination half-life of diclofenac is approximately 1.2 to 2.0 hours. The half-life refers to the time it takes for the concentration of the active substance in the blood to decrease by half.

Q: Are there any long-term effects of using Cataflam 1.5% consistently?

A: Official warnings state that the long-term use of high doses is associated with an increased risk of serious cardiovascular thrombotic events, including heart attack and stroke. The use of this drug is generally not recommended for patients with established cardiovascular disease.

Q: Is Cataflam 1.5% suitable for children or teenagers?

A: Official regulatory information typically approves the use of this systemic formulation for adolescents 14 years and older. Depending on the specific product label, certain oral solution formulations may also be available for children aged 6 years and older.

How to Store and Dispose of Cataflam 1.5%?

The storage and disposal of Cataflam 1.5% (diclofenac sodium oral solution) must comply strictly with official regulatory requirements to maintain product stability and ensure household safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F).
Protection	The product must be protected from freezing and stored away from heat and moisture.
Container	Keep the solution in its original container and ensure the cap remains tightly closed.
Safety	The medication must be kept out of the reach of children.

Disposal Instructions

To dispose of unused or expired Cataflam 1.5%, the preferred method is to use a community drug take-back program. If a program is unavailable, the medication must not be flushed down a toilet or drain. Instead, mix the product with an undesirable substance, seal it in a bag, and discard it in the household trash.